| Drug ID: | Drug181 |
|---|---|
| Drug Name: | Steroids |
| CID: | 139082353 |
| DrugBank ID: | NULL |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT05702879, , NCT03460847 |
| Molecular Formula: | C26H44N2O |
| Molecular Weight: | 400.6 g/mol |
| Isomeric SMILES: | C[C@H]([C@@H]1CC[C@H]2[C@]1(CC[C@@H]3[C@@H]2CC=C4[C@]3(CC[C@@H](C4)N(C)C)C)C)N(C)C(=O)C |
| Synonyms: | Steroid; 3alpha-Dimethylamino-20-(N-methylacetamido)pregn-5-ene; Steroids; Steroid Compound; Arnolds, Gear, Gym Candy, Juice, Pumpers, Roids, Stackers, Weight Gainers |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1299 | 139082353 | Steroids | 1576 | CYP3A4 | Homo sapiens (human) | 15955870 | Steroids results in increased expression of CYP3A4 |
| dt1300 | 139082353 | Steroids | 2554 | GABRA1 | Rattus norvegicus (Norway rat) | 18275132 | GABRA1 protein mutant form results in decreased susceptibility to steroids analog|steroids analog promotes the reaction [gamma-aminobutyric acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
| dt1301 | 139082353 | Steroids | 2561 | GABRB2 | Rattus norvegicus (Norway rat) | 18275132 | Steroids analog promotes the reaction [gamma-aminobutyric acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
| dt1302 | 139082353 | Steroids | 2566 | GABRG2 | Rattus norvegicus (Norway rat) | 18275132 | Steroids analog promotes the reaction [gamma-aminobutyric acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
| dt1303 | 139082353 | Steroids | 3565 | IL4 | Rattus norvegicus (Norway rat) | 10685002 | Steroids results in decreased expression of IL4 protein |
| dt1304 | 139082353 | Steroids | 5069 | PAPPA | Mus musculus (house mouse) | 20130263 | PAPPA protein affects the chemical synthesis of steroids |
| dt1305 | 139082353 | Steroids | 5443 | POMC | Rattus norvegicus (Norway rat) | 20021565 | POMC protein affects the reaction [ethanol results in increased abundance of steroids] |
| dt1306 | 139082353 | Steroids | 5443 | POMC | Rattus norvegicus (Norway rat) | 1668613 | POMC protein alternative form affects the abundance of steroids |
| dt1307 | 139082353 | Steroids | 103142 | Rdh9 | Mus musculus (house mouse) | 17270348 | RDH9 protein results in increased metabolism of steroids |
| dt1308 | 139082353 | Steroids | 6770 | STAR | Rattus norvegicus (Norway rat) | 12699903 | [manganese chloride results in decreased expression of STAR protein] which results in decreased chemical synthesis of steroids |
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05702879 | Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success | NULL | UNKNOWN | Insel Gruppe AG, University Hospital Bern | Ulcerative Colitis | DRUG: Ozanimod|DRUG: TNF Inhibitor|DRUG: Steroids… | Details |
| NCT05284136 | Exclusion Diet vs corticosteroIds in patientS With activE Crohn's Disease | PHASE2|PHASE3 | UNKNOWN | Assistance Publique - Hôpitaux de Paris | Crohn Disease | DIETARY_SUPPLEMENT: Crohn's disease exclusion die… | Details |
| NCT04999228 | Top Down Versus Step up in Pediatric Ulcerative Colitis | PHASE4 | RECRUITING | Children's Hospital of Fudan University | Ulcerative Colitis|Infliximab|Children | DRUG: Infliximab|DRUG: Corticosteroids | Details |
| NCT04564638 | Long-term Outcome of Patients With Acute Ulcerative Colitis After First Course of Intravenous Corticosteroids | NULL | COMPLETED | Tampere University Hospital | Ulcerative Colitis | DRUG: Corticosteroid | Details |
| NCT03942861 | Sonographic Assessment in Severe Ulcerative Colitis Patients Admitted for Intravenous Corticosteroids and Eligible for Infliximab Rescue Therapy; a Prospective Clinician-blinded Observational Study Protocol. | NULL | UNKNOWN | Copenhagen University Hospital at Herlev | Ulcerative Colitis|Ultrasound Therapy; Complicati… | DRUG: Solu-Medrol | Details |
| NCT03833596 | Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD) | PHASE4 | TERMINATED | McMaster University | Crohn's Disease | DRUG: Prednisone|DIETARY_SUPPLEMENT: Exclusive En… | Details |
| NCT03460847 | Fecal Microbiota Alterations in Steroid Refractory Active Colitis Ulcerosa | NULL | COMPLETED | Medical University of Graz | Colitis, Ulcerative | DRUG: Steroids | Details |
| NCT02922374 | Ulcerative Colitis Endoscopic Index of Severity and Fecal Calprotectin to Predict the Reaction to Corticosteroids of Acute Severe Ulcerative Colitis | PHASE1|PHASE2 | UNKNOWN | Jinling Hospital, China | Acute Severe Colitis (ASC) | DRUG: corticosteroids | Details |
| NCT02665845 | Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis). | PHASE3 | COMPLETED | Centre Hospitalier Universitaire de Saint Etienne | Ulcerative Colitis | DRUG: 5-ASA|DRUG: Corticosteroids | Details |
| NCT02619552 | Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease | NULL | COMPLETED | University of Maryland, Baltimore | Crohn's Disease|IBD | DRUG: Anti-TNF|DRUG: Anti-TNF|DRUG: Steroids | Details |
| NCT02425852 | A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis | PHASE4 | COMPLETED | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Ulcerative Colitis | DRUG: Azathioprine|DRUG: Infliximab|DRUG: Prednis… | Details |
| NCT02324699 | Corticosteroids With Vedolizumab in Crohn's Disease | PHASE4 | TERMINATED | Icahn School of Medicine at Mount Sinai | Crohn's Disease | DRUG: Prednisone|DRUG: Placebo|DRUG: Vedolizumab | Details |
| NCT02033408 | Manipulating the Microbiome in IBD by Antibiotics and FMT | NA | COMPLETED | Shaare Zedek Medical Center | Exacerbation of Ulcerative Colitis|Ulcerative Col… | DRUG: AB (antibiotics)|DRUG: CS (corticosteroids)… | Details |
| NCT01941589 | Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis | PHASE4 | COMPLETED | Sheba Medical Center | Ulcerative Colitis | DRUG: oral 5-ASA+/-topical 5-ASA+IV corticosteroi… | Details |
| NCT01536535 | Predicting Response to Standardized Pediatric Colitis Therapy | PHASE4 | COMPLETED | Connecticut Children's Medical Center | Ulcerative Colitis | DRUG: Mesalazine|DRUG: IV Corticosteroid|DRUG: Or… | Details |
| NCT00702611 | Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative Colitis | PHASE4 | TERMINATED | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | Ulcerative Colitis | DEVICE: Granulocyte Monocyte Apheresis (GMA-Apher… | Details |
| NCT00672763 | Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease | PHASE4 | WITHDRAWN | Imperial College London | Crohn's Disease | DRUG: Colecalciferol D3 (Vigantol Oil)|DRUG: Medi… | Details |
| NCT00514982 | Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome | PHASE2 | WITHDRAWN | National Institute of Allergy and Infectious Diseases (NIAID) | Hermanski-Pudlak Syndrome|Colitis|Cytokines|Lymph… | DRUG: Mesalamine|DRUG: Infliximab|DRUG: Corticost… | Details |
| NCT00269438 | New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: 5 ASA, enemas, suppositories, corticosteroi… | Details |
| NCT00265772 | Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis | PHASE4 | UNKNOWN | Hôpital Necker-Enfants Malades | Crohn's Disease|Pediatric | DRUG: MODULEN IBD (R) (specific Enteral Nutrition… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
Early management of acute severe UC in the biologics era: development and inter…
PMID: 36171080
Year: 2023
Relationship Type:
Treatment
Score: 6.5
OBJECTIVES: We aimed to determine whether changes in acute severe colitis (ASC) management have translated to improved outcomes and to develop a simp…
Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhi…
PMID: 36123319
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Cancer patients treated with immune check point inhibitors are at risk of developing severe colitis. However, the efficacy and safety of …
Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and B…
PMID: 36122389
Year: 2022
Relationship Type:
Treatment
Score: 6.5
OBJECTIVES: Colectomy rates following acute severe ulcerative colitis have plateaued around 20% despite intravenous corticosteroid and intensified an…
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active U…
PMID: 36006011
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Corticosteroid-free remission is an important treatment goal for patients with ulcerative colitis [UC]. The corticosteroid-spari…
Early Intestinal Ultrasound Predicts Intravenous Corticosteroid Response in Hos…
PMID: 35695823
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Our aim was to determine if transabdominal intestinal ultrasound changes after 48 +/- 24 h of intravenous corticosteroids can pr…
Evaluation of exclusive enteral nutrition and corticosteroid induction treatmen…
PMID: 35672586
Year: 2022
Relationship Type:
Treatment
Score: 6.5
To induce remission in luminal paediatric Crohn's disease (CD), the ESPGHAN/ECCO guideline recommends treatment with exclusive enteral nutrition (EEN…
Steroid Use and Risk of Nonalcoholic Fatty Liver Disease in Patients With Infla…
PMID: 35648974
Year: 2023
Relationship Type:
Association
Score: 6.5
GOALS: We sought to evaluate the association of steroids with nonalcoholic fatty liver disease (NAFLD) among patients with inflammatory bowel disease…
Corticosteroid-free efficacy and safety outcomes in patients receiving tofaciti…
PMID: 35574426
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Here, we report steroid-free …
Prospective validation of AIIMS index as a predictor of steroid failure in pati…
PMID: 35474175
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Optimal outcomes in acute severe ulcerative colitis (ASUC) are related to time-bound management based upon early prediction of response t…
Real-world characteristics, treatment experiences and corticosteroid utilisatio…
PMID: 35397501
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience an…
Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulc…
PMID: 35274323
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: The increasing incidence of older-onset ulcerative colitis (UC), which has a higher risk of surgery, is a global health issue. However, d…
Physician education can minimize inappropriate steroid use in patients with inf…
PMID: 35263960
Year: 2022
Relationship Type:
Association
Score: 6.5
BACKGROUND/AIMS: Epidemiological data on steroid use in South Korean patients with inflammatory bowel disease (IBD) are limited. We documented the st…
Patient preferences for treatment in steroid resistant ulcerative colitis - a d…
PMID: 35142585
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIM: Understanding treatment preferences in those patients who are not responding to corticosteroids for ulcerative colitis is importa…
Influence of Corticosteroid Use on Short- and Long-Term Outcomes of Biologic Th…
PMID: 35094254
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Corticosteroids (CS) are widely used to treat Crohn's disease (CD) and ulcerative colitis (UC), but are not recommended as maintenance th…
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progre…
PMID: 34843987
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND & AIMS: Crohn's disease (CD) patients included in the Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX) trial start…
Subcutaneous golimumab induced and maintained clinical response in a child with…
PMID: 34559136
Year: 2021
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Golimumab is a fully human antitumor necrosis monoclonal antibody that can be administered by either subcutaneous injection or intraven…
Success of Cyclosporin and Tofacitinib Combination Therapy in a Patient With Se…
PMID: 34398196
Year: 2021
Relationship Type:
Treatment
Score: 6.5
At present, the conventional therapies for acute severe ulcerative colitis (ASUC) mainly include corticosteroids, cyclosporin, and biological agents.…
Twist1 contributes to developing and sustaining corticosteroid resistance in ul…
PMID: 34335965
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Rationale: Corticosteroid resistance (CR) is a serious drawback to steroid therapy in patients with ulcerative colitis (UC); the underlying mechanism…
The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failur…
PMID: 34261387
Year: 2021
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: One-third of patients with acute severe ulcerative colitis (ASC) fail to respond to intravenous corticosteroids (IVCS) and require second…
Corticosteroid enhances epithelial barrier function in intestinal organoids der…
PMID: 33575854
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Corticosteroids (CS), first-line therapeutics for Crohn's disease (CD) with moderate or severe disease activity, were found to restore intestinal per…